Tag: ABCL

This is an update to my original 2025 AbCellera investment thesis. I am keeping that piece as a record of the original case. This update is about what has changed and what I am watching now.

My ABCL thesis is becoming more specific. The question is no longer only whether AbCellera has an interesting AI-powered antibody-discovery platform. The more important question is whether the company can convert that platform into clinical evidence that changes how investors value the business.

That makes the next set of milestones meaningful. AbCellera expects topline Phase 2 data for ABCL635 in the third quarter of 2026, Phase 1 data for ABCL575 in the fourth quarter, and an IND or CTA submission for ABCL688 in 2027. None of those outcomes is guaranteed. But they give the investment case real events against which it can be tested.

The platform now has to earn clinical credibility

The original attraction of AbCellera was the possibility that its discovery platform, data and integrated capabilities could improve the route from biological target to antibody candidate. That remains the foundation of the story. Platform claims are easier to make than they are to prove, though.

Clinical progress is where the abstraction becomes more concrete. ABCL635 is in a Phase 1/2 study, with the company expecting topline Phase 2 data in the third quarter of 2026. AbCellera has said the Phase 1 portion supported moving into Phase 2 after doses were well tolerated, with no observed liver toxicity or serious adverse events in the interim assessment. That is not proof of commercial success, but it is a more useful signal than a slide deck about platform potential.

ABCL575 is expected to produce Phase 1 topline data in the fourth quarter of 2026. Management has also stated that it currently has no plans to develop that programme beyond Phase 1. I read that as a reminder that not every programme has to become a blockbuster for the platform to create value. It also means I should not give ABCL575 more weight in the thesis than the evidence justifies.

There is more than one shot on goal

What still appeals to me is that AbCellera is not purely a single-asset biotech story. The company has partner programmes and royalty interests alongside its own internal pipeline. ABCL688, an autoimmune candidate from its GPCR and ion-channel platform, is expected to move toward an IND or CTA submission in 2027.

That does not eliminate risk. Partner activity, milestone revenue and royalty economics can be difficult to forecast. The value of multiple shots on goal is not that every one succeeds. It is that the company has several routes through which its discovery and development capabilities could create value over time.

The balance sheet buys time, not certainty

At 31 March 2026, AbCellera reported $504.7 million in cash, cash equivalents and marketable securities. That is a meaningful resource for a company investing in internal programmes and infrastructure. It gives management time to pursue the upcoming clinical milestones without making the next quarter the only thing that matters.

It should not be treated as a free pass. Cash, equivalents and marketable securities were $533.8 million at the end of 2025, and AbCellera remained loss-making in the first quarter. Revenue increased to $8.3 million from $4.2 million in the prior-year quarter, but I view that cautiously because the company’s revenue can be milestone-driven and uneven.

What would strengthen my conviction

• ABCL635 produces credible Phase 2 data and the data supports a clear development path.
• ABCL575 delivers a clean Phase 1 readout, even if the strategic value is primarily platform validation.
• ABCL688 progresses toward its planned 2027 filing.
• The company demonstrates that partner activity and internal programmes can coexist without the platform becoming an expensive science project.

Where I could be wrong

• Early clinical signals may not translate into meaningful efficacy or commercial value.
• Clinical timelines can slip, data can disappoint and development costs can rise.
• AbCellera has no marketed proprietary drugs, so the internal-pipeline case remains unproven.
• Partner fees and milestones can make revenue volatile and difficult to model.

My view now

I still see ABCL as a high-risk, high-uncertainty holding. The reason I remain interested is not a claim that the platform has already won. It is that the next twelve to eighteen months should produce clearer evidence about whether AbCellera can turn an interesting discovery engine into a clinically validated and commercially relevant business.

That is the test. If the clinical milestones strengthen the case, the platform narrative becomes more credible. If they do not, I need to be willing to reassess the thesis rather than defend the original idea.

Sources: AbCellera Q1 2026 Form 10-Q; my original 2025 ABCL investment thesis.

This is my personal investing commentary, not financial advice. I may own shares in AbCellera and can change my view as new information emerges.

View my Portfolio · Browse all ABCL writing

AbCellera Biologics (NASDAQ: ABCL) offers a captivating opportunity for investors intrigued by the intersection of biotechnology and artificial intelligence. While the company’s share price has ridden a bumpy road since its IPO, AbCellera’s innovative platform, robust pipeline, and strategic partnerships suggest that this “AI-native” drug discovery company may be approaching an inflection point. For those eager to invest in the next frontier of medicine, here’s why ABCL deserves a closer look in 2025.

AbCellera’s Platform Advantage: Disrupting Drug Discovery With AI

At its core, AbCellera’s business model is built around a powerful AI-molecular discovery engine. Unlike traditional biotech firms that focus on a handful of experimental drugs, AbCellera leverages data-driven insights, automation, and proprietary algorithms to discover, design, and develop antibodies for a diverse range of diseases.

Three key platform strengths stand out:

• AbCellera’s platform can tailor molecular shapes to precise biological targets, making it possible to address highly complex or previously “undruggable” conditions.
• Partnerships with Big Pharma (like Eli Lilly and AbbVie) and government agencies generate milestone payments, royalties, and research revenue, creating a diversified income stream.
• As more drug candidates move through the clinic, the platform’s value compounds, establishing recurring revenue and a broader moat against competitors.

A good analogy here is comparing AbCellera to the “Palantir of biotech”—a company driving a major shift in how problems in medicine are solved by leveraging software and rapid data integration.

Pipeline Progress: Clinical Trials and Internal Programs

For 2025, ABCL’s narrative is pivoting from platform potential to clinical translation. The flagship internal drug candidates—ABCL575 (targeting the OX-40 pathway for immune-mediated diseases) and ABCL635 (addressing hormonal balance and menopausal symptoms)—are both entering clinical trials this year. Early-stage results could validate years of scientific development and unlock tangible value.

Other highlights:

• More than 20 internal discovery programs are progressing, giving AbCellera a robust internal pipeline beyond partnered efforts.
• The company aspires to submit at least two new molecules to clinical trials per year, aiming for a sustainable cadence of product launches.
• Success with these lead candidates could broaden AbCellera’s reach into autoimmune disorders, cancer, and complex metabolic conditions.

Building a GMP manufacturing facility in Vancouver means AbCellera can soon bring its drug candidates from lab bench to human trials even faster, bolstering the “design-to-delivery” promise.

Financials, Valuation, and Investor Considerations

AbCellera’s fiscal profile presents both upside and risk. While revenues dipped in 2024 due to a drop in COVID-related partnership milestones, analysts expect revenue growth to accelerate in 2025, with a forecasted 6.1% annualized growth rate—a healthy improvement from prior years’ declines. The company remains cash-rich, with $650 million on the balance sheet and an additional $200 million in committed government capital.

What investors should weigh:

• Analyst consensus rates ABCL as a Strong Buy, with a 12-month price target of $8 (roughly a 91% gain from recent levels).
• For the bold: Long-term models see bullish scenarios with multi-bagger potential by 2030 and beyond, highlighting the transformative prospects of AI-led drug discovery.
• The biggest risks: biotech is volatile, clinical trial failures or regulatory delays could impact sentiment, and milestone revenues remain lumpy.

Valuation now appears undemanding compared to the promise of its technology, and a single high-profile clinical win could rapidly change its earnings outlook.

Actionable Insights for ABCL Investors

• Keep a close eye on Phase 1 trial results for ABCL575 and ABCL635—early data will be pivotal for sentiment and stock direction.
• Monitor announcements regarding new partnerships or major milestone payments, which will bolster the revenue story.
• Watch for expansion in the internal pipeline, as more clinical trials signal the platform’s scalability.

Before You Go: Key Takeaways

AbCellera’s investment thesis hinges on the convergence of AI, drug discovery, and scalable innovation. Backed by a strong balance sheet, cutting-edge technology, and a maturing clinical pipeline, ABCL offers investors a levered bet on the next generation of biotech breakthroughs. Volatility and execution risks are par for the biotech course, but for those with patience and a long-term mindset, AbCellera’s journey toward redefining how new medicines are found and delivered may prove transformational. In short: ABCL is a stock for believers in the future of biotech—and one with the tools to shape it.

Investors should stay tuned for clinical trial milestones in 2025 and beyond; these could prove defining moments for both the company and its stock trajectory.

2026 update: I have published a separate ABCL investment update focused on the approaching clinical readouts. This 2025 thesis remains the record of my original view.

Explore More: My Current Investment Portfolio

Interested in exploring more investment ideas and tracking how these insights play out? Check out my personal investment portfolio, it offers a look at the stocks I’m currently following and investing in, including SOFI, Tesla, Rocket Lab, and other high-potential opportunities.